Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2022.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA Adverse Event Reporting System.
Expert Opin Drug Saf
September 2024
Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Article Synopsis
- - The study focuses on the safety of PI3K inhibitors (like alpelisib and copanlisib) used in cancer treatment, revealing significant adverse effects related to metabolic and gastrointestinal disorders.
- - Using data from the FDA's Adverse Event Reporting System, researchers found unique and common adverse effects among different PI3K inhibitors, including colitis and dehydration, with alpelisib linked to specific issues like intestinal perforation.
- - The findings indicate varying safety profiles across the five PI3K inhibitors, which can help in making informed decisions about drug selection and future research directions.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Eur J Haematol
November 2023
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Objectives: We examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL).
Methods And Results: Thirty-seven patients with relapsed/refractory disease were included. The median number of prior lines of therapy was 3 (range 1-11); the median age was 69 years (range 50-89); 22% had Cumulative Illness Rating Scale (CIRS) >6 and 51% had del(17p)/TP53 mutation.
Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies.
Cancers (Basel)
April 2023
Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France.
The phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in cancer progression and in host immunity. Idelalisib was the first of this class to be approved with the second-generation Pi3 kinase inhibitors copanlisib, duvelisib and umbralisib, subsequently being approved in the United States. Real-world data are lacking, however, in relation to the incidence and toxicity of Pi3 kinase inhibitor-induced colitis.
View Article and Find Full Text PDFCurrent status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Curr Opin Oncol
September 2022
City of Hope National Medical Center, Duarte, California, USA.
Purpose Of Review: Treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) underwent paradigm shifts, with targeted agents rapidly displacing chemotherapy. Phosphoinotiside-3 kinase (PI3K) is essential for survival and proliferation of neoplastic B cells and has proven a tractable target in NHL, with four agents receiving FDA approval in the last decade. This review summarizes key data and challenges associated with use of PI3K inhibitors in routine practice.
View Article and Find Full Text PDFColitis due to idelalisib in a patient with follicular lymphoma.
Med Clin (Barc)
July 2022
Servicio de Hematología, Institut Català d'Oncologia-Institut de Recerca Josep Carreras-Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!